Multiple myeloma (MM) is a malignant plasma cell disease in which the tumor cells originate from plasma cells in the bone marrow, which are B lymphocytes that have developed to their final functional stage. Therefore multiple myeloma can be classified as B-lymphocytic lymphoma. The WHO currently classifies it as a type of B-cell lymphoma called plasma cell myeloma/plasmacytoma. Multiple myeloma is characterized by abnormal proliferation of bone marrow plasma cells with excessive production of monoclonal immunoglobulins or light chains (M proteins), and in rare patients it can be an unsecreted type of MM that does not produce M proteins. Because of the suppressed production of normal immunoglobulins, they are prone to various bacterial infections. The incidence is estimated to be 2-3/100,000, with a male to female ratio of 1.6:1, and most patients are >40 years of age. Multiple myeloma is a common disease of the hematological system, and the main manifestations are: 1. bone pain: painful sites are mainly lumbago, rib pain, and back pain. 2.Fracture: exertion, impact, bending or weight-bearing are sudden fractures. 3, anemia: weakness, dizziness, heartburn, etc. 4, kidney insufficiency or even kidney failure. 5, poor resistance: usually easy to infection, fever. 6, other manifestations: increased blood viscosity, hypercalcemia, bone masses. Middle-aged and elderly patients with the above symptoms need to go to regular hospitals to check blood routine, bone aspiration, serum protein electrophoresis + immunofixation electrophoresis, and take head and lumbar spine X-rays. Patients with confirmed multiple myeloma are recommended to be treated with chemotherapy, thalidomide, marfalan, and hematopoietic stem cell transplantation. The current treatment of choice is bortezomib (Vanco), which has fewer side effects and relatively better efficacy.